Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5726297 | 0.93 | HTR6 (0.61) | HTR6HTR2CHTR2A | |
| SCHEMBL5726139 | 0.84 | HTR6 (0.46) | HTR6HTR2CHTR2A | |
| SCHEMBL5726050 | 0.84 | HTR6 (0.65) | HTR6 | |
| SCHEMBL5726234 | 0.84 | HTR6 (0.70) | HTR6 | |
| SCHEMBL5726572 | 0.84 | HTR6 (0.52) | HTR6HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL27584383 | 0.83 | HTR6 (0.69) | HTR6 | |
| SCHEMBL5726925 | 0.82 | HTR6 (0.47) | HTR6HTR2CHTR2A | |
| SCHEMBL5725878 | 0.81 | HTR6 (0.50) | HTR6 | |
| SCHEMBL5727620 | 0.80 | HTR6 (0.58) | HTR6 | |
| SCHEMBL5726115 | 0.78 | HTR6 (0.69) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355900-B1 | HETEROCYCLYLALKYLINDOLE OR -AZAINDOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2006-05-24 | — | — | EP | claimed |
| US-20030225121-A1 | Heterocyclylalkylindole or-azaindole compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-12-04 | — | — | US | claimed |
| EP-1355900-A2 | HETEROCYCLYLALKYLINDOLE OR -AZAINDOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2003-10-29 | — | — | EP | claimed |
| US-6613781-B2 | Potential use in the treatment of a variety of central nervous system disorders such as anxiety, depression, epilepsy, obsessive-compulsive disorders, migraine, congnitive disorders, sleep disorders and schizophrenia | WYETH | 2003-09-02 | — | — | US | claimed |
| US-20020128477-A1 | Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-09-12 | — | — | US | claimed |
| WO-2002051832-A2 | HETEROCYCLYLALKYLINDOLE OR -AZAINDOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-07-04 | — | — | WO | claimed |
| EP-1355900-B1 | HETEROCYCLYLALKYLINDOLE OR -AZAINDOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20030225121-A1 | Heterocyclylalkylindole or-azaindole compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1355900-A2 | HETEROCYCLYLALKYLINDOLE OR -AZAINDOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6613781-B2 | Potential use in the treatment of a variety of central nervous system disorders such as anxiety, depression, epilepsy, obsessive-compulsive disorders, migraine, congnitive disorders, sleep disorders and schizophrenia | WYETH | 2003-09-02 | — | — | US | disclosed |
| US-20020128477-A1 | Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-09-12 | — | — | US | disclosed |
| WO-2002051832-A2 | HETEROCYCLYLALKYLINDOLE OR -AZAINDOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128477-A1 | Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | HTR6 1/4885HTR2C 4/4885HTR2A 5/4885 |
| US-20030225121-A1 | Heterocyclylalkylindole or-azaindole compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | HTR6 1/4885HTR2C 4/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.